Quinolone antibiotic labeling to include warnings of potential tendon inflammation/rupture.
Executive Summary
QUINOLONE MANUFACTURERS AGREE TO TENDONITIS/RUPTURE WARNING IN LABELING following a year of negotiations with FDA. Letters from FDA requesting that labeling changes reflect the potential for fluoroquinolone antibiotics to cause tendonitis or tendon rupture were first sent to the five manufacturers in April 1995. Although several companies initially protested the change, according to FDA, all had submitted approved labeling changes by June.
You may also be interested in...
Seeking Stronger Antibiotic Warnings, Public Citizen Sues FDA
The success of a Public Citizen lawsuit may hinge on whether the advocacy group can convince a judge that 16 months is an "unreasonable delay" in acting on a petition requesting labeling changes
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011